ArticleNature2022
Extricating human tumour immune alterations from tissue inflammation.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
8.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 95 citations in OpenAlex.
- Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma - a multicenter phase 2 trial (EPOC1802).Nature cancer · 2025Trial
- Activatable NIR-II photoacoustic probes for cancer imaging and imaging-guided therapy.Bioactive materials · 2026Review
- Multifaceted roles of chemokines in gastric cancer: From tumor microenvironment modulation to therapeutic targeting (Review).Oncology letters · 2026Review
- Molecular heterogeneity and clonal origin of CCR8Nature communications · 2026Article
- Regulatory T cells in cancer and inflammation.Signal transduction and targeted therapy · 2026Review
- Tissue-specific adaptation of human T cells is preserved during tissue inflammation.bioRxiv : the preprint server for biology · 2026Article
- An at-home blood collection device for remote immune monitoring by high-parameter flow cytometry.JCI insight · 2026Article
- IL-1-mediated inflammation promotes metastatic dissemination and resistance to EGFR-targeted therapy.NPJ precision oncology · 2026Article
- Peripheral Regulatory T Cells Display Dynamic Memory Subset Frequency and Inhibitory Marker Expression Across Pregnancy.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026Article
- Phenotypically similar but functionally distinct NK cell populations within the human maternal-fetal interface.ImmunoHorizons · 2026Article
- Postbiotics: emerging bioactive agents in cancer therapy.Cancer biology & medicine · 2026Review
- Article
- Spatial Treg niches and the therapeutic reprogramming of tumour tolerance in cancer.Frontiers in cell and developmental biology · 2026Review
- Single Cell RNA Sequencing in Colorectal Cancer Immunology: Recent Updates, Application, and Emerging Challenges.Current molecular medicine · 2026Review
- A next-generation anti-CTLA-4 probody mitigates toxicity and enhances anti-tumor immunity in mice.Nature communications · 2025Article
- Phenotyping of human platelets in response to platelet agonists and inhibitors using multiparameter flow cytometry and unbiased high-dimensional analysis.Research and practice in thrombosis and haemostasis · 2025Article
- Article
- SmartImpute is a targeted imputation framework for single-cell transcriptome data.Cell reports methods · 2025Article
- IL-1R2 promotes tumorigenesis and modulates the tumor immune microenvironment in colorectal cancer.Cancer immunology, immunotherapy : CII · 2025Article
- Functional role of P2X7 purinergic receptor in cancer and cancer-related pain.Purinergic signalling · 2025Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
12 authors at 4 institutions in 3 countries.
Florian Mair *Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-6732-5449
Jami R Erickson *Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-4549-5217
Marie FrutosoFred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-7848-1049
Andrew J KonecnyFred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.
Evan GreeneFred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.
Valentin VoilletFred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.
Nicholas J MauriceFred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-2667-472X
Anthony RongvauxDepartment of Immunology, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-7142-6533
Douglas DixonDepartment of Periodontics, School of Dentistry, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-0911-3717
Brittany BarberDepartment of Otolaryngology-Head and Neck Surgery, University of Washington, Seattle, WA, USA.
Raphael GottardoFred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.
Martin PrlicFred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA. mprlic@fredhutch.org.ORCID http://orcid.org/0000-0002-0685-9321
University of Washington · USFred Hutch Cancer Center · USCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZAUniversity of Tennessee Health Science Center · US
Funding
Diseases of Public Health Importance Training GrantT32AI007509 · NIAID · UNIVERSITY OF WASHINGTON · PI LUND, JENNIFER M · 1997 to 2024
$6.3MInflammation-driven T Cell Responses and their Dichotomous Effect on Host ImmunityR01AI123323 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PRLIC, MARTIN · 2017 to 2025
$5.0MTargeting macrophages in metastatic cancerR01CA234720 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI RONGVAUX, ANTHONY · 2019 to 2023
$2.2MHigh-Performance Compute Cluster for Comprehensive Cancer and Infectious Diseases ResearchS10OD028685 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BRADLEY, PHILIP · 2020 to 2020
$2.0MThe effect of peri-mucositis and peri-implantitis on innate-like T cell function and anti-bacterial immunityR21DE026565 · NIDCR · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DIXON, DOUGLAS RAYMOND, PRLIC, MARTIN · 2017 to 2018
$488kProfiling and leveraging bystander T cells within the tumor microenvironmentF99CA245735 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MAURICE, NICHOLAS JOSEPH · 2019 to 2021
$94kNCI NIH HHS F99 CA245735NCI NIH HHS R01 CA234720NIAID NIH HHS R01 AI123323NIAID NIH HHS T32 AI007509NIDCR NIH HHS R21 DE026565NIH HHS S10 OD028685
Abstract
Immunotherapies have achieved remarkable successes in the treatment of cancer, but major challenges remain
Indexed as
NeoplasmsHumansImmunotherapyInflammationT-Lymphocytes, RegulatoryTumor Microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.